Related Experiment Videos
Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor
Sabine Borngraeber1, Mary-Jane Budny, Grazia Chiellini
1Department of Biochemistry/Biophysics, University of California, San Francisco, CA 94143-2240, USA.
Summary
Researchers identified a selective thyroid hormone receptor beta agonist, GC-24, revealing how its unique structure enables specific binding. This discovery advances selective nuclear receptor therapeutics for endocrine diseases.
Area of Science:
- Molecular Biology
- Endocrinology
- Structural Biology
Background:
- Developing selective therapeutics for nuclear receptors is crucial for endocrine disease treatment.
- Achieving selectivity is challenging due to similar hormone-binding cavities among receptors.
- Human thyroid hormone receptor beta (hTRβ) is a key target, with limited selective agonists known.
Purpose of the Study:
- To elucidate the structural basis of the high selectivity and agonist activity of GC-24 for hTRβ.
- To understand how GC-24's unique benzyl substitution influences receptor binding and activation.
Main Methods:
- X-ray crystallography was used to determine the structure of hTRβ bound to GC-24 at 2.8-Å resolution.
- Structural analysis focused on ligand-receptor interactions and conformational changes.
Main Results:
- GC-24, a selective hTRβ agonist, features a benzyl substitution at the 3' position, differing from natural thyroid hormone.
- The benzyl group induces shifts in receptor helices, accommodating its larger size within the binding pocket.
- Despite structural rearrangements, the GC-24-hTRβ complex maintains tight coactivator association and full agonist activity.
Conclusions:
- The structural data explain GC-24's agonist activity and unique isoform specificity for hTRβ.
- Ligand recognition specificity arises from forming a novel hydrophobic cluster involving both ligand and protein components.
- This study provides a structural foundation for designing highly selective nuclear receptor modulators.